Skip to main content
. Author manuscript; available in PMC: 2016 Dec 7.
Published in final edited form as: Cancer. 2008 May 15;112(10):2112–2118. doi: 10.1002/cncr.23427

FIGURE 1.

FIGURE 1

Probability of progression-free survival in the International Randomized Study of Interferon (IFN) and STI571 (IRIS) trial among imatinib-treated patients without a complete cytogenetic response (CCyR) at 12 months or patients who achieved a CCyR with or without a concurrent major molecular response (MMR) (BCR-ABL reduction of at least 3 log). P was <.001 for the overall comparison, .013 for the comparison of patients without a CCyR with those with a CCyR plus MMR, and .007 for the comparison of patients with a CCyR with or without a MMR.29